weight loss, Food and Drug Administration

Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of 2025 as production capacity increases, its finance chief said on Monday.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1s—medications containing the same active ingredients as the blockbuster weight-loss drugs but sold at a much lower price.
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.
Eli Lilly's Global Expansion Plan for Blockbuster Drug Mounjaro
Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, and Mexico by 2025. With 900 million potential patients, the company aims to meet growing global demand alongside competitor Novo Nordisk.
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says
(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.
Pharmalittle: We’re reading about Lilly and Roche weight loss drugs, FDA and compounders, and more
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers
STAT2d
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
The Hill7d
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes
Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...
Fierce Pharma8d
Want a piece of Lilly's $27B US manufacturing investment? Please send your application
Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...